| Private Placement / Financing Transactions
MBrace Therapeutics: The company raised $85 million of Series B venture funding in a deal led by TPG on November 21, 2023, putting the company’s pre-money valuation at $65 million. Venrock, Alta Partners, Cowen Healthcare Investments, Avidity Partners, and other undisclosed investors also participated in the round. The company is a developer of anti-tumor monoclonal human recombinant antibodies intended to treat cancer patients.
Quotient Therapeutics: The company raised $50 million of venture funding in a deal led by Flagship Pioneering on November 22, 2023. The company focuses on the study of genetic variation at the cellular level to discover therapeutics informed by new links between genes and disease.
Alto Neuroscience: The company raised $45 million of Series C venture funding in a deal led by InVivium Capital on November 21, 2023, putting the company’s pre-money valuation at $175 million. Alexandria Venture Investments, Lightswitch Capital, Alpha Wave Global, What If Ventures, Windham Venture Partners, Alkeon Capital Management, Franklin Templeton, Point72 Asset Management and Eli Lilly, Company Foundation and other undisclosed investors also participated in the round. The company is a developer of a psychiatric drug development platform intended to help patients with central nervous system conditions.
Cradle Bio: The company raised $24 million of Series A venture funding in a deal led by Index Ventures on November 23, 2023. Kindred Capital, Chris Gibson and Thomas H. Glocer also participated in the round. The company is a developer of an algorithm and artificial intelligence tool designed to help biologists design improved proteins.
ImpriMed: The company raised KRW 30 billion of Series A venture funding in a deal led by SoftBank Ventures Asia on November 22, 2023. Samyang Chemical Group, Byuksan, SK Telecom, Murex Partners, Mayo Clinic Platform, Han River Partners, Korea Development Bank, and Ignite Innovation also participated in the round. The company is a developer of a personalized drug response prediction technology designed to offer veterinarians information for treating canine lymphoma.
Alcyone Therapeutics: The company raised $17.3 million in Series F venture funding from undisclosed investors on November 22, 2023, putting the company’s pre-money valuation at $80 million. The company integrates gene-based therapeutics, precision delivery, and quality manufacturing into a tailored clinical approach for complex neurological conditions.
Bioxodes: The company raised EUR 8.5 million of Series A venture funding from undisclosed investors on November 21, 2023, putting the company’s pre-money valuation at EUR 21.3 million. The company is an operator of a clinical-stage biopharmaceutical company intended to help thrombosis and neuroinflammation in hemorrhagic stroke patients.
Prealize Health: The company raised $7 million of Series D venture funding from undisclosed investors on November 21, 2023, putting the company’s pre-money valuation at $40 million. The company uses AI-powered predictive analytics to help payers and providers reduce healthcare costs and improve clinical outcomes.
Floy: The company raised EUR 5.4 million of venture funding in a deal led by HV Capital on November 24, 2023. 10x Founders, All Iron Ventures, Saarbruecker 21, and Xdeck Ventures also participated in the round. The company is a developer of artificial intelligence-driven software designed to support radiologists in detecting complex and hard-to-identify diseases.
Reglagene: The company raised $3.8 million of Series A1 venture funding from undisclosed investors on November 21, 2023. The company is developing a tubulin-targeting therapy that is orally administered, well-tolerated, and blood-brain barrier penetrant for the treatment of brain cancers.
HOPPR: The company raised $3 million of venture funding in a deal led by Health2047 on November 26, 2023. UnitedHealth Group and other undisclosed investors also participated in this round. The company is a developer of an Artificial Intelligence foundation model designed for medical imaging.
Trailhead Biosystems: The company raised $3 million of venture funding from undisclosed investors on November 20, 2023. The company develops industrial-grade human cells from induced stem cells for drug discovery and cell therapies.
Windgap Medical: The company raised $2.3 million of venture funding in the form of convertible debt from undisclosed investors on November 20, 2023. The company is a developer of auto-injectors and drug-delivery devices designed to treat patients with severe allergies.
Reservoir Neuroscience: The company raised $2.1 million of venture funding from undisclosed investors on November 21, 2023. The company develops novel therapeutics to treat and heal the blood-brain barrier.
|
